Savara (SVRA) Cash from Financing Activities (2010 - 2026)
Savara (SVRA) reported Cash from Financing Activities of -$195000.0 for Q1 2026, down 108.41% year-over-year from $2.3 million in Q1 2025, and down 100.14% on a QoQ basis from $135.6 million in Q4 2025.
Savara (SVRA) has 17 years of Cash from Financing Activities data on file, last reported at -$195000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 108.41% year-over-year to -$195000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135.3 million (up 12.89% YoY) and the FY2025 annual result came in at $137.8 million, up 17.2% from the prior year.
- Cash from Financing Activities fell to -$195000.0 in Q1 2026 per SVRA's latest filing, from $135.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $135.6 million in Q4 2025 and bottomed at -$843000.0 in Q4 2024.
- The 5-year median for Cash from Financing Activities is $49000.0 (2024), against an average of $19.9 million.
- The widest annual swing landed in 2023, when Cash from Financing Activities surged 7475600.0%; it then slumped 189.09% in 2025.
- Tracing SVRA's Cash from Financing Activities over 5 years: stood at $1000.0 in 2022, then soared by 789400.0% to $7.9 million in 2023, then slumped by 110.68% to -$843000.0 in 2024, then surged by 16180.66% to $135.6 million in 2025, then slumped by 100.14% to -$195000.0 in 2026.
- Per Business Quant, the three latest SVRA Cash from Financing Activities figures stand at -$195000.0 (Q1 2026), $135.6 million (Q4 2025), and -$23000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | -195,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -195,000.00 |
| Mar 31, 2026 | -195,000.00 |
| Dec 31, 2025 | 135.56 Mn |
| Dec 31, 2025 | 135.56 Mn |
| Sep 30, 2025 | -23,000.00 |
| Sep 30, 2025 | -23,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | 2.32 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | -843,000.00 |
| Dec 31, 2024 | -843,000.00 |
| Sep 30, 2024 | 118.32 Mn |
| Sep 30, 2024 | 118.32 Mn |
| Jun 30, 2024 | 55,000.00 |
| Jun 30, 2024 | 55,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Dec 31, 2023 | 7.90 Mn |
| Dec 31, 2023 | 7.90 Mn |
| Sep 30, 2023 | 74.76 Mn |
| Sep 30, 2023 | 74.76 Mn |
| Jun 30, 2023 | 104,000.00 |
| Jun 30, 2023 | 104,000.00 |
| Mar 31, 2023 | 26,000.00 |
| Mar 31, 2023 | 26,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | 88,000.00 |
| Jun 30, 2022 | 88,000.00 |
| Mar 31, 2022 | -1,000.00 |
| Mar 31, 2022 | -1,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Sep 30, 2021 | 10,000.00 |
| Sep 30, 2021 | 10,000.00 |
| Jun 30, 2021 | 324,000.00 |
| Jun 30, 2021 | 324,000.00 |
| Mar 31, 2021 | 120.47 Mn |
| Mar 31, 2021 | 120.47 Mn |
| Sep 30, 2020 | 1.83 Mn |
| Sep 30, 2020 | 1.83 Mn |
| Jun 30, 2020 | 2.33 Mn |
| Jun 30, 2020 | 2.33 Mn |
| Mar 31, 2020 | -466,000.00 |
| Mar 31, 2020 | -466,000.00 |
| Dec 31, 2019 | 25.25 Mn |
| Dec 31, 2019 | 25.25 Mn |
| Sep 30, 2019 | 5.71 Mn |
| Sep 30, 2019 | 5.71 Mn |
| Jun 30, 2019 | 19.06 Mn |
| Jun 30, 2019 | 19.06 Mn |
| Mar 31, 2019 | 4.90 Mn |
| Mar 31, 2019 | 4.90 Mn |
| Dec 31, 2018 | 9.10 Mn |
| Dec 31, 2018 | 9.10 Mn |
| Sep 30, 2018 | 45.81 Mn |
| Sep 30, 2018 | 45.81 Mn |
| Jun 30, 2018 | 16,000.00 |
| Jun 30, 2018 | 16,000.00 |
| Mar 31, 2018 | 271,000.00 |
| Mar 31, 2018 | 271,000.00 |
| Dec 31, 2017 | 50.76 Mn |
| Dec 31, 2017 | 50.76 Mn |
| Sep 30, 2017 | 435,000.00 |
| Sep 30, 2017 | 435,000.00 |
| Jun 30, 2017 | 55.32 Mn |
| Jun 30, 2017 | 55.32 Mn |
| Mar 31, 2017 | -421,000.00 |
| Mar 31, 2017 | -421,000.00 |
| Dec 31, 2016 | 100,000.00 |
| Dec 31, 2016 | 100,000.00 |
| Sep 30, 2016 | 4.32 Mn |
| Sep 30, 2016 | 4.32 Mn |
| Jun 30, 2016 | -6.72 Mn |
| Jun 30, 2016 | -6.72 Mn |
| Mar 31, 2016 | 7.42 Mn |
| Mar 31, 2016 | 7.42 Mn |
| Dec 31, 2015 | -8.07 Mn |
| Dec 31, 2015 | -8.07 Mn |
| Sep 30, 2015 | 14.82 Mn |
| Sep 30, 2015 | 14.82 Mn |
| Jun 30, 2015 | 2.03 Mn |
| Jun 30, 2015 | 2.03 Mn |
| Mar 31, 2015 | -6,000.00 |
| Mar 31, 2015 | -6,000.00 |
| Dec 31, 2014 | 20.24 Mn |
| Dec 31, 2014 | 20.24 Mn |
| Sep 30, 2014 | 2.17 Mn |
| Sep 30, 2014 | 2.17 Mn |
| Jun 30, 2014 | 3.90 Mn |
| Jun 30, 2014 | 3.90 Mn |
| Mar 31, 2014 | 7.98 Mn |
| Mar 31, 2014 | 7.98 Mn |
| Dec 31, 2013 | -116,289.00 |
| Dec 31, 2013 | -116,289.00 |
| Sep 30, 2013 | -242,612.00 |
| Sep 30, 2013 | -242,612.00 |
| Jun 30, 2012 | -3,170.00 |
| Jun 30, 2012 | -3,170.00 |
| Mar 31, 2012 | -47,742.00 |
| Mar 31, 2012 | -47,742.00 |
| Dec 31, 2011 | 15.64 Mn |
| Dec 31, 2011 | 15.64 Mn |
| Mar 31, 2011 | 20.96 Mn |
| Mar 31, 2011 | 20.96 Mn |
| Dec 31, 2010 | -2.00 |
| Dec 31, 2010 | -2.00 |